Cosmos Health vs Cellyan Biotechnology Co.
Cosmos Health is the larger business, with $65.3m of revenue in fiscal 2025 against $13.4m for Cellyan Biotechnology Co. (4.9 times as much). Cosmos Health grew faster (19.9% against -33.9%). Cellyan Biotechnology Co. kept more of each dollar of sales as profit: a net margin of -8.5% against -29.3%.
| Latest fiscal year | Cosmos HealthCOSM, 2025 | Cellyan Biotechnology Co.HKPD, 2026 |
|---|---|---|
| Revenue | $65.3m | $13.4m |
| Revenue growth | 19.9% | -33.9% |
| Net income | −$19.1m | −$1.1m |
| Operating margin | — | -17.8% |
| Net margin | -29.3% | -8.5% |
| Return on equity | -89.1% | -15.5% |
| Free cash flow | −$8.5m | −$787,072 |
| Cash | $715,674 | $221,841 |
| Total debt | $15.6m | $877,904 |
| Debt to equity | — | 9.1% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 163 | — |
| Market value | $24.4m | $30.1m |
| Price vs our value range | — | — |
| Moat score | 22 (Weak) | — |
| Insider trades, 12 months | 21 buys, 0 sales | 0 buys, 0 sales |